The main purpose of the core unit is to provide an in vivo model for the growth of chronic myelogenous leukemia (CML) and normal stem/progenitor cells. NOD/scid animals will be used in experiments to investigate the basic biology of CML progenitors and to model potential therapeutic interventions. The core will breed and maintain NOD/scid mice in the Barrier Animal Facility within the Center for Comparative Medicine at Baylor College of Medicine. The facility uses strict standard operating procedures designed to keep all animals specific pathogen free (SPF). Core personnel will perform all experimental manipulations on NOD/scid mice for the individual project investigators. The core personnel will also provide in vitro manipulation of CML and normal hematopoietic progenitors. For example, the core will provide tissue culture for testing purging protocols and for retroviral vector transduction. The core personnel have special interest and expertise in retroviral vector gene marking technology and will implement serial and clone-specific gene marking techniques as required by the individual projects. The core will provide harvested bone marrow cells from transplanted NOD/scid mice and other tissues involved with leukemic disease as required by the individual investigators. The core personnel will coordinate with the flow cytometry and FISH laboratories for analysis of NOD/scid bone marrow cells and tissues.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA049639-09A1
Application #
6102554
Study Section
Project Start
1998-09-30
Project End
1999-01-31
Budget Start
Budget End
Support Year
9
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Gambacorti-Passerini, Carlo; Cortes, Jorge E; Lipton, Jeff H et al. (2018) Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study. Haematologica 103:1298-1307
Boddu, Prajwal; Shah, Abdul Rashid; Borthakur, Gautam et al. (2018) Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma 59:1312-1322
Kornblau, Steven M; Ruvolo, Peter P; Wang, Rui-Yu et al. (2018) Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival. Haematologica 103:810-821
Zhang, Weiguo; Ly, Charlie; Ishizawa, Jo et al. (2018) Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial. Haematologica 103:1642-1653
Alhuraiji, Ahmad; Kantarjian, Hagop; Boddu, Prajwal et al. (2018) Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol 93:84-90
Ishizawa, Jo; Nakamaru, Kenji; Seki, Takahiko et al. (2018) Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res 78:2721-2731
Boddu, Prajwal; Benton, Christopher B; Wang, Wei et al. (2018) Erythroleukemia-historical perspectives and recent advances in diagnosis and management. Blood Rev 32:96-105
Ruvolo, Peter P; Ruvolo, Vivian R; Burks, Jared K et al. (2018) Role of MSC-derived galectin 3 in the AML microenvironment. Biochim Biophys Acta Mol Cell Res 1865:959-969
Cortes, Jorge E; Gambacorti-Passerini, Carlo; Deininger, Michael W et al. (2018) Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol 36:231-237
Sasaki, Koji; Kantarjian, Hagop; O'Brien, Susan et al. (2018) Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer 124:1160-1168

Showing the most recent 10 out of 375 publications